Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach

Emma EF Kleipool,1 Johannes AN Dorresteijn,2 Yvo M Smulders,1 Frank LJ Visseren,1,2 Mike JL Peters,1 Majon Muller1

ABSTRACT

Due to an increasing number of older adults with (risk factors for) cardiovascular disease (CVD), the sum of older adults eligible for lipid-lowering drugs will increase. This has risen questions about benefits and harms of lipid-lowering therapy in older adults with a varying number of (cardiovascular) comorbidities and functional status. The heterogeneity in physical and functional health increases with age, leading to a much wider variety in cardiovascular risk and life expectancy than in younger adults. We suggest treatment decisions on hypercholesterolaemia in adults aged ≥75 years should shift from a strictly 10-year cardiovascular risk-driven approach to a patient-centred and lifetime benefit-based approach. With this, estimated 10-year risk of CVD should be placed into the perspective of life expectancy. Moreover, frailty and safety concerns must be taken into account for a risk–benefit discussion between clinician and patient. Based on the Dutch addendum ‘Cardiovascular Risk Management in (frail) older adults’, our approach offers more detailed information on what not to initiate or discontinue therapy than standard guidelines. Instead of using traditional risk estimating tools which tend to overestimate risk of CVD in older adults, use a competing risk adjusted, older adults-specific risk score (available at https://u-prevent.com). By filling in a patient’s (cardiovascular) health profile (eg, cholesterol, renal function), the tool estimates risk of CVD and models the effect of medication in terms of absolute risk reduction for an individual patient. Using this tool can guide doctors and patients in making shared decisions on initiating, continuing or discontinuing lipid-lowering therapy.

INTRODUCTION

In Europe alone, at least 85 million patients have cardiovascular disease (CVD), causing 3.9 million deaths each year.1 The majority of these patients is aged ≥65 years, a number expected to grow even further in our ageing Western society. Hence, the sum of older adults eligible for lipid-lowering drugs will increase. This has risen given to clinical dilemmas on whether, and how we should treat hypercholesterolaemia in older adults, such as in patients 1, 2 and 3 presented in figure 1. All three cases present patients frequently encountered in daily clinical practice. They raise questions about the benefits and harms of lipid-lowering therapy in older adults with varying number of (cardiovascular) comorbidities and functional status. In this article we provide an overview of the current literature on lipid-lowering drugs in older adults and explain why heterogeneity of cardiovascular risk increases with age. We set out why and how estimated 10-year risk of CVD needs to be put into the perspective of a patient’s estimated life expectancy when deciding on whether or not to prescribe lipid-lowering therapy. Finally, we call for a shift from a risk-based strategy using traditional 10-year risk estimation tools to a lifetime benefit-based strategy, and provide recommendations on how to implement this in daily clinical practice.

EVIDENCE FROM TRIALS

Up until now, only one randomised clinical trial (RCT), the PROSpective Study of Pravastatin in the Elderly at Risk (PROSPER) trial,2 was specifically designed to evaluate statins versus placebo in older patients with and without pre-existing CVD. Other evidence on the benefits of lipid-lowering therapy in older adults is based on (meta-analyses of) subgroups of older patients from large RCTs including adults aged <80 years. The PROSPER trial2 included 5804 patients aged 70–82 with (high risk of) CVD. In older patients with CVD, pravastatin lowered the risk of cardiovascular events or death over a period of 3.2 years (HR: 0.78; 95% CI: 0.66 to 0.93). However, in patients without pre-existing CVD, contrary to most other primary prevention trials with effect sizes of 25%–30%,3 the relative risk (RR) reduction was only 6% and did not reach statistical significance (HR: 0.94; 0.77–1.15). This could be due to lack of power because the PROSPER trial was not designed to demonstrate a significant effect in each subgroup. Yet, this still leaves the effectiveness of statins in older adults without CVD unconfirmed. A recent meta-analysis of 28 randomised controlled trials including 14,483 patients ≥75 years of age (mean [SD] age 78.8 [2.8] years) showed that in patients with pre-existing CVD the proportional reduction in cardiovascular events was similar among all age groups (pinteraction 0.2). The RR reduction on major vascular events for patients with CVD was 0.85; 95% CI 0.73 to 0.98 in 4.9 years of time.4 In patients without pre-existing CVD, mainly using subgroup results of the PROSPER trial, a smaller proportional risk reduction was observed with increasing age (pinteraction 0.05). No significant benefit of statins was observed for patients aged ≥75 years without CVD (RR 0.92; 0.73 to 1.16). This is in line with a previously published primary prevention meta-analysis.5 Although ambiguous, of all older adults without CVD, data seem to suggest only (very) high-risk patients (eg, with diabetes) benefit from statins in terms of preventing CVD.6-8 In conclusion, previously performed trials show that lipid-lowering therapy benefits older adults at high
absolute risk of CVD, for example, those with preexisting CVD. However, these trials did not include adults aged >80 years and most likely no frail older adults, suggesting that these results may not apply to a great deal of the (frail) older patients encountered in daily clinical practice. Also, RCTs were not powered in terms of outcomes which are important in the majority of older adults, such as quality of life and functional status. According to the National Institute on Aging (NIA) placebo-controlled and pragmatic RCTs seem to be suitable to address these knowledge gaps, studying a full range of outcomes, such as quality of life, function and symptom burden related to statins. However, we foresee obstacles for conducting such a trial, as today most older adults already take lipid-lowering drugs, and the frailest patients are not able to participate in such trials. Perhaps only pragmatic deprescribing RCTs or analyses of electronic health records with details on incidence and severity of major side effects and

Figure 1  Cardiovascular risk profiles and potential treatment benefits of lipid-lowering therapy in patients 1 to 3. Estimations of pre-treatment risk of CVD and the potential treatment benefit of LLDs (ie, absolute risk reductions) are based on an older adult-specific, competing risk adjusted risk estimation tool. Estimated life expectancy is based on Holmes et al. Patients 1 and 2 have no pre-existing CVD. Except for hypertension (BP 160/90 mm Hg) and smoking, they have the same cardiovascular risk profile. Patient 1 receives vitamin D, calcium and acetaminophen and is otherwise in good health. Patient 2 receives calcium, vitamin D, a bisphosphonate, hydrochlorothiazide, amlodipine, macrogol and acetaminophen. She is in relatively good health. Both patients are currently not taking any lipid-lowering medication. Patient 3 has experienced a myocardial infarction 6 years ago, has heart failure (NYHA III), mild cognitive impairment, COPD and chronic renal failure (eGFR 30 mL/min/1.73 m²). He makes his way using a walker and uses nine drugs in total on a daily basis. He has been taking simvastatin 40 mg, without any evident side effects, once a day since his myocardial infarction. ARR, absolute risk reduction; BP, blood pressure; COPD, chronic pulmonary disease; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HT, hypertension; LDL-c, low-density lipoprotein cholesterol; LLD, lipid-lowering drug; MI, myocardial infarction; NYHA, New York Heart Association.
Additional comments
variety in cardiovascular risk factors, in older adults a much
greater burden of treatable risk factors, for example, high blood pressure or cholesterol, and competing risks (ie, the risk of non-vascular death). Consequently, they may not live long enough to experience a (new) cardiovascular event, making their 10-year risk of CVD lower than their lifetime risk of CVD (ie, the time-until-benefit exceeds life expectancy). As with cardiovascular risk, a substantial heterogeneity in life expectancy exists in older adults. For example, an average 75-year-old male has a median estimated remaining life expectancy of approximately 8–9 years. On the other hand, a 75-year-old with multiple comorbidities belonging to the ‘sickest’ 25% of the population is estimated to live a maximum of 5 years. See online supplementary appendix 2 for more information on estimating life expectancy.

**HETEROGENEITY IN CARDIOVASCULAR RISK AND LIFE EXPECTANCY**

Older adults are likely to have multimorbidity, polypharmacy and functional impairments putting them at risk of frailty. This results in a heterogeneous population ranging from very fit patients with a long remaining life span to very frail older adults. For example, an average 75-year-old male has a median estimated remaining life expectancy of approximately 8–9 years. On the other hand, a 75-year-old with multiple comorbidities belonging to the ‘sickest’ 25% of the population is estimated to live a maximum of 5 years. See online supplementary appendix 2 for more information on estimating life expectancy.

**RETHINKING 10-YEAR RISK OF CVD**

Table 1 gives an overview of the recommendations for managing hypercholesterolaemia in older adults for three major guidelines: the 2014 British National Institute for Health and Care Excellence (NICE) guideline, the 2016 European Society of Cardiology (ESC) guideline and the 2018 American Heart Association/American College of Cardiology (AHA/ACC) guideline. They all recommend that hypercholesterolaemia treatment in older adults, in principle, should not differ from those in younger patients, and is based on estimated 10-year cardiovascular risk. As previously experienced, CVD is a major risk factor for the occurrence of new cardiovascular events, all patients with pre-existing CVD are at very high 10-year risk of CVD and therefore eligible for lipid-lowering drugs. For patients without wider variety in baseline cardiovascular risk exists compared with younger adults. Differences in pre-treatment risk do not significantly influence the RR reduction established by lipid-lowering therapy, but pre-treatment cardiovascular risk does heavily influence the potential absolute risk reduction. For example, in two patients with the same estimated life expectancy, benefits of lipid-lowering therapy are greatest in the patient with the highest pre-treatment risk of CVD. However, it is important to realise that high pre-treatment risk of CVD does not necessarily mean a high lifetime risk of CVD. This can be explained by competing risks: older adults are likely to have one or more chronic diseases, which puts them at high risk of non-vascular death. Consequently, they may not live long enough to experience a (new) cardiovascular event, making their 10-year risk of CVD lower than their lifetime risk of CVD (ie, the time-until-benefit exceeds life expectancy). As with cardiovascular risk, a substantial heterogeneity in life expectancy exists in older adults. For example, an average 75-year-old male has a median estimated remaining life expectancy of approximately 8–9 years. On the other hand, a 75-year-old with multiple comorbidities belonging to the ‘sickest’ 25% of the population is estimated to live a maximum of 5 years. See online supplementary appendix 2 for more information on estimating life expectancy.

**Table 1** Guideline recommendations

| Guideline               | With CVD                                                                 | Without CVD                                                                 | Additional comments                                                                 |
|-------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| NICE 201420 | Treat in the same way as younger adults. Decisions on whether or not to start LLD therapy should be made after an informed physician–patient discussion about the risks and benefits of statin treatment | Treat in the same way as younger adults. Decisions on whether or not to start therapy should be made after an informed physician–patient discussion about the risks and benefits of LLD treatment | No/limited evidence exists to validate CV benefits and side effects of LLDs in oldest patients. Yet, the important effect of age on CV risk suggests all older people should be offered a LLD. Take benefits from lifestyle modifications, patient preference, comorbidities, polypharmacy, frailty and life expectancy into account |
| ESC 201622 | Treat in the same way as younger adults. However, recommendations should be followed with caution and common sense | Treat in the same way as younger adults. However, recommendations should be followed with caution and common sense | We encourage a discussion with patients regarding quality of life, life potentially gained, total burden of drug treatment and uncertainties of benefit. Monitor adverse effects closely, reconsider treatment periodically |
| AHA/ACC 201823 | 70–75 years: treat in the same way as younger adults. >75 years: it is reasonable to initiate moderate/high intensity statins. Weigh potential CV risk reduction against adverse effects, drug–drug interactions, frailty and patient preferences before initiating therapy. Continue high-intensity statins if well-tolerated. | 70–75 years: treat in the same way as younger adults. >75 years: clinical assessment, risk discussion. It may be reasonable to stop statins when functional decline, multimorbidity, frailty or reduced life-expectancy limits the potential benefits of statins | |

AHA/ACC, American Heart Association/American College of Cardiology; CV, cardiovascular; CVD, cardiovascular disease; ESC, European Society of Cardiology; LLD, lipid-lowering drug; NICE, National Institute for Health and Care Excellence.
CVD, guidelines recommend estimating 10-year risk with traditional risk tools, which state that the majority of older adults are at (very) high 10-year risk of CVD because of their age (and presence of additional cardiovascular risk factors). As a consequence, almost every older adult—with or without CVD—is eligible for use of a lipid-lowering drug. Traditional risk estimation tools do not adjust for competing risks, and consequently, tend to overestimate an older patient’s actual 10-year risk of CVD. Also, as described above, a large number of older adults, especially those with multimorbidity or frailty, will not live as long as 10 years. On a group level, the beneficial effects of lipid-lowering drugs in terms of establishing a clinically relevant difference in preventing CVD occur approximately 2–3 years after initiating treatment. For some older patients, the time-until-benefit of lipid-lowering therapy therefore may exceed their life expectancy. Every guideline acknowledges that evidence on benefits and harms of lipid-lowering drugs in older patients, especially patients without CVD, is limited. They all mention that treatment decisions should be guided by clinical judgement, and recommend to include comorbidity, frailty, adverse effects, adherence and patient preference in the decision to treat or not. Compared to the 2014 NICE and the 2016 ESC guidelines, the 2018 AHA/ACC guideline clarifies in more detail what should be meant by this. Also, the latter guideline is the only guideline addressing when to consider deprescribing a lipid-lowering drug (although only for older patients without pre-existing CVD). An important shortcoming of all guidelines is that they are single-disease based, solely based on data from clinical trials in relatively young and fit adults and give advice on how to treat ‘average’ patients. Recently, a multidisciplinary addendum ‘Cardiovascular Risk Management (CVRM) in (frail) older adults’ was published in the Netherlands. Based on current, best-available evidence and expert opinion, it provides advice on starting, continuing or discontinuing lipid-lowering drugs in fit and frail older adults. The recommendations may be seen as progressive, because more attention is paid to frailty status, not initiating and deprescribing lipid-lowering therapy than in standard guidelines. Our recommendations presented below are based on this addendum.

**MAKING TREATMENT DECISIONS: FROM A RISK-BASED TO A BENEFIT-BASED APPROACH**

Treatment decisions on hypercholesterolaemia in adults aged ≥75 years call for shift from a strictly 10-year cardiovascular risk-driven approach to a patient-centred and lifetime benefit-based approach in which shared decision-making is key. With the latter, estimated 10-year risk of CVD is also taking into consideration, but only after putting this into the perspective of life expectancy and by including potential negative effects of lipid-lowering therapy. To avoid overestimating an individual patient’s 10-year risk of CVD with traditional (older adults-specific) risk tools, we propose to use a competing risk adjusted, older adults-specific risk score. Contrary to traditional risk tools, this tool has been validated in studies that also included older patients and patients with several comorbidities. The tool is available free of charge on http://U-Prevent.com, and models the effect of medication changes in terms of 10-year absolute risk reduction (or number needed to treat). Together with the patient, risk is estimated after filling in easily available clinical parameters, such as cholesterol levels, blood pressure, renal function and number of drugs used. The clear graphics (figure 4, online supplementary appendix) can help facilitate a physician–patient discussion on whether the potential lifetime benefits versus the impact potential adverse effects are sufficient to validate therapy for the years left to live. This tool is less suitable in very frail patients, those with multimorbidity or those with a limited life expectancy, as these patients were not included in the (cohort) studies the tool algorithm is based on. Randomised studies on deprescribing lipid-lowering therapy in older adults are scarce, and there is no need to deprescribe therapy solely because of chronological age. However, we believe that there are two reasons to consider deprescribing lipid-lowering therapy: limited life expectancy (<1–2 years) and adverse effects overshadowing preventive treatment benefits. In patients with a limited lifespan, lifetime risk of CVD has fallen to such a degree that it is unlikely treatment will prevent (new) cardiovascular events, even in patients at (very) high baseline risk of CVD. In these patients, quality of life, functional status and doing no harm take priority over preventing (fatal) CVD. Although observational studies observed increased risk of cardiovascular events after deprescribing statins in older patients, randomised deprescribing trials observed no increase in mortality after deprescribing statins, and a potential to improve quality of life.

**ADVERSE EFFECTS OF LIPID-LOWERING THERAPY**

Common concerns on lipid-lowering therapy in older adults are statin-related muscle symptoms (eg, myalgia, weakness) leading to physical inabilities, drug–drug interactions and polypharmacy. ‘Real-life’ observational studies suggest a higher prevalence of statin-related muscle symptoms compared with those reported in RCTs (8%–11% vs 1%–5%). And although data suggest that statins are similarly tolerated in adults aged ≥75 years and younger adults, this may not be the case on individual patient level; pre-existing functional limitations and polypharmacy could make older patients more prone to the muscle symptoms, functional decline and drug–drug interactions. These harmful effects may disproportionally affect frail older adults because they have an increased likelihood of poor functional status to begin with. Clear evidence for this is lacking. However, considering the large number of older adults taking statins, the likelihood of under-reporting (non-specific) muscle symptoms and their potential to majorly impact functionality, it is important to pay attention to adverse effects in every older patient.

**PRACTICAL IMPLICATIONS**

For use in daily clinical practice, we constructed a flowchart (figure 3) with advice on when to initiate, continue and deprescribe lipid-lowering drugs in fit and frail adults aged ≥75 years. The recommendations are in line with the Dutch addendum ‘CVRM in (frail) older adults’. The cut-off of ≥75 years of age is arbitrary, but consistent with the majority of available evidence. For each individual patient, a discussion of estimated lifetime risk of CVD, risk of adverse effects and consideration of patient preferences should precede the decisions on prescribing lipid-lowering drugs. In older patients with pre-existing CVD with a reasonable life expectancy (more than 1–2 years), lifetime risk of CVD is considered high enough to benefit from initiating or continuing lipid-lowering therapy. However, in case of severe negative effects (eg, side effects) or if life expectancy is limited (less than 1–2 years), the benefits of lipid-lowering therapy do not outweigh potential adverse effects of treatment. For frail older patients without pre-existing CVD we propose to deprescribe or not to initiate lipid-lowering treatment. Their lifetime risk of CVD is not sufficient enough to benefit from lipid-lowering therapy in terms of preventing a cardiovascular event in the time left to live. Also, frailty may exacerbate adverse effects.
effects of therapy. In fit older adults with a life expectancy of ≥2 years, only initiate or continue lipid-lowering therapy if a patient is at high risk of CVD; diabetes mellitus, total cholesterol >8 mmol/L, blood pressure >180/110 mm Hg and/or a 10-year risk of CVD estimated with an competing risk adjusted, older adults-specific risk tool >20%. In low-risk patients without CVD, lifetime risk of CVD is too low to meaningfully benefit from therapy. At the same time, therapy potentially exposes these patients to adverse effects and promotes polypharmacy.

RECOMMENDATIONS FOR PATIENTS 1–3
The following treatment recommendations are based on the Dutch addendum ‘CVRM in (frail) older adults’.\(^3\) COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; CVRM, cardiovascular risk management; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

CONCLUSION
In the older population, a wider distribution of cardiovascular risk exists compared with younger adults due to heterogeneity in physical and functional health. Treatment decisions on hypercholesterolaemia in adults aged ≥75 years should call for shift from a strictly 10-year cardiovascular risk-driven approach to a patient-centred and lifetime benefit-based approach by putting estimated 10-year risk of CVD into the perspective of remaining life expectancy, patients preferences, frailty and potential adverse effects of treatment. When estimating 10-year risk of CVD, use a competing risk adjusted, older adults-specific risk score instead of traditional risk tools as the latter tend to overestimate risk of CVD. Evidence on the benefits versus harms of lipid-lowering therapy is inconclusive and inconsistent for a large number of older adults, particularly adults aged >80 years and frail older adults. We therefore advocate for randomised (de)prescribing trials studying a full range of outcomes, such as quality of life, functional capacity and symptom burden related to statins.

Contributors EEFK drafted the manuscript. All authors fully read, reviewed and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Emma EK Kleipool http://orcid.org/0000-0002-9518-6797
Frank LJ Visseren http://orcid.org/0000-0003-3951-5223

REFERENCES
1 Timmis A, Townsend N, Gale C, et al. European Society of cardiology: cardiovascular disease statistics 2017. *Eur Heart J* 2018;39:508–79.
2. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial. *Lancet* 2002;360:1623–30.

3. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;380:581–90.

4. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;393:407–15.

5. Savarese G, Gotto AM, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2013;62:2090–9.

6. Ramos R, Comas-Culi M, Marti-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. *BMC* 2018;362.

7. Ridker PM, Lonn E, Fayyad NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. *Circulation* 2017;135:1979–81.

8. Bezir J, Moore N, Mansiaux Y, et al. Real-Life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study. *Am J Med* 2019;132:740–8.

9. Singh S, Ziemann S, Go AS, et al. Statins for primary prevention in older Adults-Moving toward evidence-based decision-making. *J Am Geriatr Soc* 2018;66:2188–96.

10. Kent DM, Rothwell PM, Ioannidis JPA, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials* 2010;11:85.

11. Thansassoulis G, Williams K, Altobelli KK, et al. Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease. *Circulation* 2016;133:1574–81.

12. Stam-Sloeb MC, Visseren FL, Wouter Jukema J, et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in elderly patients. *Clin Res Cardiol* 2017;106:56–68.

13. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. *Lancet* 2005;365:434–41.

14. Jaspers NEM, Ridker PM, Dorresteijn JAN, et al. The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. *Curr Opin Lipidol* 2018;29:436–44.

15. Dorresteijn JAN, Kaasenbrood L, Cook NR, et al. How to translate clinical trial results into gain in healthy life expectancy for individual patients. *BMC* 2016;352.

16. Wolters M, Koller MT, Wittman JCM, et al. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiology* 2009;20:555–61.

17. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. *Arch Intern Med* 2006;166:605–9.

18. Organisation for Economic Co-operation and Development (OECD). OECD StatExtracts. Available: http://stats.oecd.org/Index.aspx. DataSetCode=HEALTH_STAT [Accessed 26 Jul 2018].

19. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. *JAMA* 2001;285:2750–6.

20. Duerden M, O’Rynn N, Oreushi N. Cardiovascular risk assessment and lipid modification: NICE guideline. *Br J Gen Pract* 2015;65:378–80.

21. National Institute for Health and Care Excellence (NICE). Lipid modification therapy for preventing cardiovascular disease. NPulApNoNo.

22. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).[Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;37:2315–81.

23. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ASCVD/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2019;73:3168–209.

24. Barter PJ, Waters DD. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. *J Lipid Res* 2018;12:957–62.

25. Addendum. Kwetsbare ouderen bij CVRM. Available: https://richtlijndatabase.nl/richtlijn/addendum_kwetsbare_ouderen_bij_cvm/dyslipidemie_bij_kwetsbare_ouderen.html

26. Cooney MT, Selmer R, Lindman A, et al. Cardiovascular risk estimation in older persons: score O.P. Eur J Prev Cardiol. 2018;23:1093–103.

27. Saeed A, Nambi V, Sun W, et al. Short-term Global Cardiovascular Disease Risk Prediction in Older Adults. *J Am Coll Cardiol* 2019;73:3168–209.

28. Jaspers NEM, Blaha MJ, Mushakta K, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. *Eur Heart J* 2019. doi:10.1093/eurheartj/ehz239. [Epub ahead of print: 18 May 2019]

29. U-Prevent you are in control. Available: www.u-prevent.com

30. Kutner JS, Blachford PJ, Taylor DM, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med* 2015;175:691–700.

31. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. *Ther Adv Drug Saf* 2015;6:212–33.

32. Rossello X, Pococh SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. *J Am Coll Cardiol* 2015;66:1273–85.

33. Giral P, Neumann A, Weil A, et al. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. *Eur Heart J* 2019. doi:10.1093/eurheartj/ehz458. [Epub ahead of print: 30 Jul 2019].

34. Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a prospective population-based study. *BMC Med* 2013;11:e20333.

35. Bruckert E, Hayem G, Depager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. *Cardiovasc Drugs Ther* 2005;19:403–14.

36. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetics and nondiabetes patients. *Clin Ther* 2007;29:1761–70.

37. Nanna MG, Nava AM, Wang TY, et al. Statin use and adverse effects among adults >75 years of age: insights from the patient and provider assessment of lipid management (PALM) registry. *J Am Heart Assoc* 2018;7:e008546.

38. Strandberg TE, Kolehmainen L, Vuoio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. *AMA* 2014;312:1136–44.

39. Thai M, Hilmer S, Pearson S-A, et al. Prevalence of potential and clinically relevant Statin-Drug Interactions in frail and robust older inpatients. *Drugs Aging* 2015;32:849–56.

40. Morley JE, Mahon G. Statins and the nursing home. *J Am Med Dir Assoc* 2013;14:853–4.